Survey of 500 pts with systemic rheumatic diseases during the COVID-19 pandemic showed few who discontinuations Rx - 2.2% D/C for fear of immunosuppression; 3.8% for shortages (mostly HCQ); 2.6%) for resp infx and 6% for side-effects. https://t.co/2BJIYeBSIu